Method Of Predicting The Tumor Response To Dna Methylation Inhibitors And Alternative Therapeutic Regimens For Overcoming Resistance

  • Published: Sep 30, 2015
  • Earliest Priority: Mar 27 2014
  • Family: 11
  • Cited Works: 35
  • Cited by: 0
  • Cites: 2
  • Additional Info: Cited Works Published
Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The present invention provides a method for predicting the sensitivity of a patient suffering from a cancer disease to DNA methylation inhibitor therapy, which comprises determining in vitro in cancer cells taken from the patient and comparing with values for parent type of cells - the level of expression of at least one bromodomain containing gene, and/or - the level of expression of at least one bromodomain containing protein and/or - the mutations involving the non-synonymous change in amino acid sequence of at least one bromodomain containing gene and/or - the half maximal inhibitory concentration (IC 50 ) of a DNA methylation inhibitor and/or a histone demethylase inhibitor, wherein the increase in the half maximal inhibitory concentration of the DNA methylation inhibitor and/or the histone demethylase inhibitor signifies cross-resistance, and/or - the half maximal inhibitory concentration (IC 50 ) of a selective BET bromodomain inhibitor, wherein the decrease in the half maximal inhibitory concentration of the selective BET bromodomain inhibitor signifies sensitivity. The invention further provides a combination therapy of cancers using bromodomain inhibitors in combination with DNA methylation inhibitors.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Sep 30, 2015
  • Application: Mar 27, 2014
    EP EP 14161897 A
  • Priority: Mar 27, 2014
    EP EP 14161897 A

Download Citation


Sign in to the Lens

Feedback